health
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Why this matters: health reporting relevant to everyday decisions and well-being.
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.&#x A0; Its next act — this time as a co-lead — was revealed Monday. Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat along with Revolution’s daraxonrasib led to a durable responses in the large majority of pancreatic cancer patients who received both medicines. Continue to STAT+ to read the full story…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop